[{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"ae2cba1f-c1b0-4377-acd9-157b4b00473b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06222203","created_at":"2024-01-24T14:23:14.000Z","updated_at":"2024-07-02T16:34:25.563Z","phase":"","brief_title":"Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)","source_id_and_acronym":"NCT06222203","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CDKN2A • CDKN2B","pipe":" | ","alterations":" CDKN2A mutation","tags":["CDKN2A • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 12/31/2034","primary_completion_date":" 12/31/2034","study_txt":" Completion: 12/31/2035","study_completion_date":" 12/31/2035","last_update_posted":"2024-06-17"},{"id":"99825282-13d0-4537-9611-5aeeb9d9b074","acronym":"PCEDP","url":"https://clinicaltrials.gov/study/NCT02206360","created_at":"2021-01-18T10:19:50.126Z","updated_at":"2024-07-02T16:35:01.200Z","phase":"","brief_title":"Pancreatic Cancer Early Detection Program","source_id_and_acronym":"NCT02206360 - PCEDP","lead_sponsor":"White Plains Hospital","biomarkers":" BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-05-24"},{"id":"08b82509-fbbd-4719-b2fe-d7db759f217f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05529069","created_at":"2022-09-06T17:03:18.330Z","updated_at":"2024-07-02T16:35:07.866Z","phase":"Phase 2","brief_title":"Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients","source_id_and_acronym":"NCT05529069","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification","tags":["TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Jaypirca (pirtobrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/25/2023","start_date":" 01/25/2023","primary_txt":" Primary completion: 04/28/2027","primary_completion_date":" 04/28/2027","study_txt":" Completion: 04/28/2027","study_completion_date":" 04/28/2027","last_update_posted":"2024-04-24"},{"id":"46d378ac-a32a-49b5-8f63-3c539b277a13","acronym":"QPCS","url":"https://clinicaltrials.gov/study/NCT04104230","created_at":"2021-01-18T20:04:23.369Z","updated_at":"2024-07-02T16:35:09.050Z","phase":"","brief_title":"Quebec Pancreas Cancer Study","source_id_and_acronym":"NCT04104230 - QPCS","lead_sponsor":"George Zogopoulos","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 03/12/2012","start_date":" 03/12/2012","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-17"},{"id":"94e4c4f4-2bce-41ab-89c2-a3acf0b6d2b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03250078","created_at":"2021-01-18T16:03:25.897Z","updated_at":"2024-07-02T16:35:12.111Z","phase":"","brief_title":"A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals","source_id_and_acronym":"NCT03250078","lead_sponsor":"Nuvance Health","biomarkers":" BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-04-01"},{"id":"107dd190-b738-4816-b39c-d6828e427b79","acronym":"PancreasScan","url":"https://clinicaltrials.gov/study/NCT05006131","created_at":"2021-08-16T17:54:43.106Z","updated_at":"2024-07-02T16:35:13.981Z","phase":"","brief_title":"Pancreatic Cancer Screening for At-risk Individuals","source_id_and_acronym":"NCT05006131 - PancreasScan","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 07/10/2020","start_date":" 07/10/2020","primary_txt":" Primary completion: 03/10/2027","primary_completion_date":" 03/10/2027","study_txt":" Completion: 03/10/2028","study_completion_date":" 03/10/2028","last_update_posted":"2024-03-19"},{"id":"b3f90894-0222-4bf0-bf99-93337787e6c0","acronym":"MELVEC","url":"https://clinicaltrials.gov/study/NCT04605822","created_at":"2021-01-19T20:31:24.580Z","updated_at":"2024-07-02T16:35:14.168Z","phase":"","brief_title":"Melanoma Detection in Switzerland With VECTRA","source_id_and_acronym":"NCT04605822 - MELVEC","lead_sponsor":"University Hospital, Basel, Switzerland","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A mutation","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation"],"overall_status":"Completed","enrollment":" Enrollment 455","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2024-03-19"},{"id":"c92b8794-1c47-49f1-88e3-148924bb13cc","acronym":"BISCAY","url":"https://clinicaltrials.gov/study/NCT02546661","created_at":"2021-01-18T12:19:22.211Z","updated_at":"2024-07-02T16:35:15.193Z","phase":"Phase 1","brief_title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02546661 - BISCAY","lead_sponsor":"AstraZeneca","biomarkers":" HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL","pipe":" | ","alterations":" PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification","tags":["HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/03/2016","start_date":" 10/03/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-12"},{"id":"5d2f8237-eb79-4c19-a52b-8af11ae90986","acronym":"","url":"https://clinicaltrials.gov/study/NCT02775461","created_at":"2021-01-18T13:36:36.959Z","updated_at":"2024-07-02T16:35:21.683Z","phase":"","brief_title":"Pancreas Registry and High Risk Registry","source_id_and_acronym":"NCT02775461","lead_sponsor":"Icahn School of Medicine at Mount Sinai","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MSH2","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1116","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 11/01/2033","primary_completion_date":" 11/01/2033","study_txt":" Completion: 11/01/2033","study_completion_date":" 11/01/2033","last_update_posted":"2024-01-30"},{"id":"8086c59c-d398-45e2-9f6f-5158e36590e7","acronym":"PalboSarc","url":"https://clinicaltrials.gov/study/NCT03242382","created_at":"2021-01-18T16:01:11.999Z","updated_at":"2024-07-02T16:35:22.689Z","phase":"Phase 2","brief_title":"Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.","source_id_and_acronym":"NCT03242382 - PalboSarc","lead_sponsor":"Grupo Espanol de Investigacion en Sarcomas","biomarkers":" CDKN2A • CDK4","pipe":" | ","alterations":" CDKN2A mutation • CDK4 overexpression","tags":["CDKN2A • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation • CDK4 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/31/2017","start_date":" 03/31/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-01-23"},{"id":"abd7c1e1-e507-42de-a1cb-233356ada31d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05015816","created_at":"2021-08-20T14:53:16.509Z","updated_at":"2024-07-02T16:35:26.004Z","phase":"","brief_title":"MoleGazer Development Feasibility Study","source_id_and_acronym":"NCT05015816","lead_sponsor":"Oxford University Hospitals NHS Trust","biomarkers":" CDKN2A • CDK4","pipe":" | ","alterations":" CDKN2A mutation • CDK4 mutation","tags":["CDKN2A • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation • CDK4 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 550","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/12/2026","study_completion_date":" 02/12/2026","last_update_posted":"2023-12-18"},{"id":"fc21c219-c013-4138-9fe8-07a9c22cead0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05013216","created_at":"2021-08-19T14:52:56.438Z","updated_at":"2024-07-02T16:35:38.156Z","phase":"Phase 1","brief_title":"Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer","source_id_and_acronym":"NCT05013216","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1","pipe":" | ","alterations":" KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation","tags":["KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-09-04"},{"id":"1ee70366-b7a8-4f46-abc0-90483806c589","acronym":"","url":"https://clinicaltrials.gov/study/NCT01744652","created_at":"2021-01-18T07:38:47.984Z","updated_at":"2024-07-02T16:35:46.306Z","phase":"Phase 1","brief_title":"Dasatinib and Crizotinib in Advanced Cancer","source_id_and_acronym":"NCT01744652","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • ALK • MET • CDKN2A • DDR2 • CTGF","pipe":" | ","alterations":" BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification","tags":["BRAF • ALK • MET • CDKN2A • DDR2 • CTGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2023-06-07"},{"id":"cb6e094e-2742-489c-80fc-e3915d2584c6","acronym":"PREPAIRD","url":"https://clinicaltrials.gov/study/NCT05740111","created_at":"2023-02-22T15:01:18.890Z","updated_at":"2024-07-02T16:35:54.968Z","phase":"","brief_title":"The PREPAIRD Study: Personalized Surveillance for Early Detection of Pancreatic Cancer in High Risk Individuals","source_id_and_acronym":"NCT05740111 - PREPAIRD","lead_sponsor":"Oslo University Hospital","biomarkers":" TP53 • STK11 • CDKN2A • PRSS1","pipe":" | ","alterations":" TP53 mutation • STK11 mutation • CDKN2A mutation","tags":["TP53 • STK11 • CDKN2A • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • STK11 mutation • CDKN2A mutation"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 12/31/2042","primary_completion_date":" 12/31/2042","study_txt":" Completion: 12/31/2042","study_completion_date":" 12/31/2042","last_update_posted":"2023-02-22"},{"id":"c4d79bb8-8b6f-470a-8b96-2d4499daedea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03965845","created_at":"2021-01-18T19:30:39.173Z","updated_at":"2024-07-02T16:36:03.785Z","phase":"Phase 1b/2","brief_title":"A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors","source_id_and_acronym":"NCT03965845","lead_sponsor":"Calithera Biosciences, Inc","biomarkers":" KRAS • CDKN2A","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • CDKN2A mutation","tags":["KRAS • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • CDKN2A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • telaglenastat (CB-839)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 06/25/2019","start_date":" 06/25/2019","primary_txt":" Primary completion: 09/24/2021","primary_completion_date":" 09/24/2021","study_txt":" Completion: 09/24/2021","study_completion_date":" 09/24/2021","last_update_posted":"2022-09-19"},{"id":"c10fd239-8d18-4b6b-bd31-e11709e5a58c","acronym":"TCOG","url":"https://clinicaltrials.gov/study/NCT03174574","created_at":"2021-01-18T15:39:08.219Z","updated_at":"2024-07-02T16:36:08.600Z","phase":"","brief_title":"Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer.","source_id_and_acronym":"NCT03174574 - TCOG","lead_sponsor":"Mayo Clinic","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A mutation","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 08/17/2016","start_date":" 08/17/2016","primary_txt":" Primary completion: 01/25/2019","primary_completion_date":" 01/25/2019","study_txt":" Completion: 01/25/2019","study_completion_date":" 01/25/2019","last_update_posted":"2022-06-16"},{"id":"de3ecf6b-3b4c-409e-bd4d-5f880ce8753e","acronym":"SIGNATURE","url":"https://clinicaltrials.gov/study/NCT02187783","created_at":"2021-01-18T10:12:32.699Z","updated_at":"2024-07-02T16:36:57.957Z","phase":"Phase 2","brief_title":"LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)","source_id_and_acronym":"NCT02187783 - SIGNATURE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CDKN2A • CCND1 • CDK4 • CDK6 • CCND3","pipe":" | ","alterations":" CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification","tags":["CDKN2A • CCND1 • CDK4 • CDK6 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 08/25/2014","start_date":" 08/25/2014","primary_txt":" Primary completion: 01/17/2018","primary_completion_date":" 01/17/2018","study_txt":" Completion: 01/17/2018","study_completion_date":" 01/17/2018","last_update_posted":"2019-07-18"},{"id":"4d133b89-ab6f-4697-a9cc-81c89fdaf99b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02846714","created_at":"2021-01-18T13:58:26.920Z","updated_at":"2024-07-02T16:36:59.822Z","phase":"","brief_title":"Family Lifestyle Actions and Risk Education Study","source_id_and_acronym":"NCT02846714","lead_sponsor":"University of Utah","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A mutation","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2019-05-08"},{"id":"19be524b-4248-4054-97ea-82c45566fa0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02540876","created_at":"2021-01-18T12:17:34.359Z","updated_at":"2024-07-02T16:37:00.329Z","phase":"Phase 1","brief_title":"Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02540876","lead_sponsor":"University of Chicago","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A deletion • CDKN2A mutation","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • CDKN2A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ilorasertib (ABT348)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 09/08/2015","start_date":" 09/08/2015","primary_txt":" Primary completion: 02/08/2019","primary_completion_date":" 02/08/2019","study_txt":" Completion: 02/08/2019","study_completion_date":" 02/08/2019","last_update_posted":"2019-04-22"},{"id":"f9282959-da1a-4277-9eb2-00db5cf8baa3","acronym":"CAPS4","url":"https://clinicaltrials.gov/study/NCT00714701","created_at":"2021-01-18T02:40:29.986Z","updated_at":"2024-07-02T16:37:07.112Z","phase":"","brief_title":"Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)","source_id_and_acronym":"NCT00714701 - CAPS4","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • STK11 • CDKN2A","pipe":" | ","alterations":" STK11 mutation • PALB2 mutation • CDKN2A mutation","tags":["BRCA1 • BRCA2 • STK11 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • PALB2 mutation • CDKN2A mutation"],"overall_status":"Completed","enrollment":" Enrollment 631","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/01/2016","study_completion_date":" 07/01/2016","last_update_posted":"2018-09-07"}]